Be on the Lookout for This One Cancer-Battling IPO

The world’s richest doctor, Patrick Soon-Shiong, is back in the spotlight this week with an IPO of one of his spinoff companies, NantKwest Inc. (Nasdaq: NK).

Soon-Shiong owns a private conglomerate called NantWorks. It maintains a family of subsidiary companies specializing in advanced semi-conductor technology, supercomputing, advanced networks, and augmented intelligence. Each works within a larger scheme to diagnose and treat cancer patients.

But NantWorks is privately held, so before this week, the only real way to get publicly traded access was via a partnership they had with Sorrento Therapeutics (Nasdaq: SRNE), which saw its stock go from under $5 in December, to over $25 this month.

This week, when NantKwest went public, the company offered 8.3 million shares at $25. Investor appetite quickly swelled as shares surged 39% to $34.64 at the close of the market.

Investors understand the groundbreaking technology and pedigree of the NantWorks brand. They’re doing everything possible to get a piece of the booming biotech juggernaut.

NantKwest leverages the innovative research methods of the NantWorks conglomerate, but primarily focuses on immunotherapy drug production.

Immunotherapy uses the body’s own defenses to fight cancer and other deadly diseases. This approach has become quite popular over the traditional highly toxic methods of chemotherapy.

NantKwest grows immune system cells, better known as natural killer cells, and provides them to patients through CAR-T therapy. Unlike competitors, NantKwest produces cells that are “off the shelf” and don’t require customization for each patient.

According to Soon-Shiong, using natural killer cells mimics “the natural order of the immune system,” giving patients a safer, non-toxic alternative to chemotherapy chemicals.

If you still want to hop on the NantWorks bandwagon, it’s not too late! Soon-Shiong told the L.A. Times that he intends to take his medical records company NantHealth public by the end of this year. Keep your eyes peeled.

Ben Benoy

Ben Benoy
Editor, BioTech Intel Trader

What You Need to Know About the Safe-Asset Slaughter!

You’re not going to believe what’s on the horizon…

The final bubble of the recent financial crisis is about to burst. When it pops – it could be as soon as November 2014 – millions of Americans will be financially devastated… But others will have the opportunity to get much richer.

This controversial video reveals how you can end up on the winning side of the coming carnage…

Click to Learn More
Categories: Biotech

About Author

Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.